Common water pill may boost liver cancer treatment

NCT ID NCT03107416

First seen May 10, 2026 · Last updated May 14, 2026 · Updated 2 times

Summary

This study tests adding bumetanide, a common water pill, to a standard procedure that blocks blood flow to liver tumors. The goal is to find a safe dose and see if it helps control tumor growth. About 30 adults with liver cancer that cannot be removed by surgery will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Consent and follow-up only)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Consent and follow-up only)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth (Consent and follow-up only)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester (Consent and follow-up only)

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.